‘Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation’ by Ali et al. – reassess the evidence, shall we?-Reference-Cited by-同舟云学术

‘Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation’ by Ali et al. – reassess the evidence, shall we?

Published:2023-04-25 Issue:4 Volume:33 Page:88-89
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Saiz-Rodríguez Miriam¹,Zubiaur Pablo²,Abad-Santos Francisco²³

Affiliation:

1. Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, Burgos

2. Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria La Princesa (IP), Universidad Autónoma de Madrid (UAM)

3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference14 articles.

1. Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.;Ali;Pharmacogenet Genomics,2022

2. Variability in platelet responsiveness to clopidogrel among 544 individuals.;Serebruany;J Am Coll Cardiol,2005

3. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.;Matetzky;Circulation,2004

4. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.;Kazui;Drug Metab Dispos,2010

5. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.;Scott;Clin Pharmacol Ther,2013